Actively Recruiting
Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment
Led by Beijing Tiantan Hospital · Updated on 2025-03-28
1204
Participants Needed
1
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to explore the efficacy and safety of Human Urinary Kallidinogenase for acute ischemic stroke patients receiving intravenous thrombolysis and/or endovascular treatment.
CONDITIONS
Official Title
Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Acute ischemic stroke in the anterior circulation within 24 hours of symptom onset
- NIHSS score between 4 and 25 at enrollment
- Receiving intravenous recombinant tissue plasminogen activator (rt-PA) or TNK-tPA, or endovascular treatment including intra-arterial thrombolysis, mechanical thrombectomy, or bridging therapy
- Independent in daily activities before stroke (mRS score 1 or less)
- Patient or legal representative able and willing to sign informed consent
You will not qualify if you...
- Alberta Stroke Program Early Computed Tomography Score (ASPECT) of 6 or less on preoperative CT scan
- Prior treatment with Human Urinary Kallidinogenase after stroke onset
- Allergy to Human Urinary Kallidinogenase, related drugs, or other medications and foods
- History of coagulation disorders, systemic bleeding, thrombocytopenia, or hemorrhagic diseases at enrollment
- Use of anticoagulants such as warfarin or rivaroxaban, or heparin within 48 hours after stroke onset
- Regular use of ACE inhibitor antihypertensive drugs within one week before enrollment
- Chronic liver disease or liver dysfunction with elevated ALT/AST (>3 times upper limit normal)
- Kidney dysfunction or dialysis with elevated serum creatinine (>2 times upper limit normal)
- Severe cardiopulmonary disease unsuitable for the study
- Contraindications to intravenous thrombolysis or endovascular treatment
- Life expectancy less than 3 months due to lethal diseases
- Pregnancy, lactation, or women of childbearing age not using effective contraception or lacking negative pregnancy test
- Inability to complete the study due to mental illness, cognitive or emotional disorders, physical or geographical factors
- Participation in another clinical trial currently
- Other conditions deemed unsuitable by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100070
Actively Recruiting
Research Team
W
Wang Yilong, MD, PhD
CONTACT
W
Wang Tingting, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here